Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Consensus Rating of “Hold” by Brokerages

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) has earned an average rating of “Hold” from the five analysts that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $38.3333.

PHAR has been the topic of several research reports. Canaccord Genuity Group began coverage on Pharming Group in a research note on Friday, April 10th. They issued a “buy” rating and a $37.00 target price on the stock. Weiss Ratings cut shares of Pharming Group from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Wall Street Zen downgraded shares of Pharming Group from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Finally, Zacks Research raised shares of Pharming Group from a “strong sell” rating to a “hold” rating in a research report on Friday, April 10th.

Pharming Group Stock Performance

PHAR opened at $12.61 on Friday. The company has a market capitalization of $892.18 million, a price-to-earnings ratio of 78.79 and a beta of -0.04. The business’s 50-day moving average price is $13.12 and its two-hundred day moving average price is $15.40. Pharming Group has a 1 year low of $9.54 and a 1 year high of $21.34. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.63 and a quick ratio of 2.06.

Pharming Group (NASDAQ:PHAR) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.12). The firm had revenue of $72.45 million for the quarter, compared to analyst estimates of $92.06 million. Pharming Group had a return on equity of 4.64% and a net margin of 3.30%. Equities analysts expect that Pharming Group will post 0.6 EPS for the current fiscal year.

Institutional Trading of Pharming Group

Institutional investors and hedge funds have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC acquired a new position in Pharming Group during the second quarter valued at approximately $32,000. SmartHarvest Portfolios LLC acquired a new position in shares of Pharming Group during the 4th quarter worth approximately $224,000. Millennium Management LLC acquired a new position in shares of Pharming Group during the 4th quarter worth approximately $360,000. Finally, NewEdge Advisors LLC raised its stake in shares of Pharming Group by 11,310.3% during the 4th quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock worth $510,000 after purchasing an additional 28,615 shares in the last quarter. Institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.